Results 121 to 130 of about 27,684 (225)

Engineering the Electrochemiluminescence Microenvironment: Mechanistic Roles of Nanomaterials in Aptamer‐Based Sensors

Small Structures, Volume 7, Issue 9, September 2026.
This review highlights how nanomaterials have transformed electrochemiluminescence (ECL) aptasensors beyond their traditional role as supports. It examines their emerging roles as new ECL luminophores and active regulators of the ECL microenvironment within aptasensors.
Ana Díaz‐Fernández, Noemí de‐los‐Santos‐Álvarez, María Jesús Lobo‐Castañón   +2 more
wiley   +1 more source

Clinical effect of MUC1 and its relevance to BRAF V600E mutation in papillary thyroid carcinoma: a case–control study

, 2018
Quan Li,* Wen-Xu Jin,* Yi-Xiang Jin, Zhou-Ci Zheng, Xiao-Fen Zhou, Qing-Xuan Wang, Dan-Rong Ye, Yi-Han Sun, Xiao-Hua Zhang, Ou-Chen Wang, En-Dong Chen, Ye-Feng Cai Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Wenzhou Medical
Zheng Z, Jin W, Wang O, Wang Q, Zhang X, Ye D, Cai Y, Li Q, Jin Y, Zhou X, Sun Y, Chen E   +11 more
core  

Development of New Models of Oral Mucosa to Investigate the Impact of the Structure of Transmembrane Mucin-1 on the Mucosal Pellicle Formation and Its Physicochemical Properties

Biomedicines
The mucosal pellicle (MP) is a biological film protecting the oral mucosa. It is composed of bounded salivary proteins and transmembrane mucin MUC1 expressed by oral epithelial cells.
Clément Nivet, Irma Custovic, Laure Avoscan, Floris J. Bikker, Aline Bonnotte, Eric Bourillot, Loïc Briand, Hélène Brignot, Jean-Marie Heydel, Noémie Herrmann, Mélanie Lelièvre, Eric Lesniewska, Fabrice Neiers, Olivier Piétrement, Mathieu Schwartz, Christine Belloir, Francis Canon   +16 more
doaj   +1 more source

MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer

Biomedicines
Patients with pancreatic neuroendocrine tumors (pNETs) have limited access to effective targeted agents and invariably succumb to progressive disease. MUC1-C is a druggable oncogenic protein linked to driving pan-cancers. There is no known involvement of
Hiroki Ozawa, Naoki Haratake, Ayako Nakashoji, Tatsuaki Daimon, Atrayee Bhattacharya, Keyi Wang, Keisuke Shigeta, Atsushi Fushimi, Kazumasa Fukuda, Yohei Masugi, Ryo Yamaguchi, Minoru Kitago, Hirofumi Kawakubo, Yuko Kitagawa, Donald Kufe   +14 more
doaj   +1 more source

Establishment of primary cell cultures from canine mammary gland malignant tumours: a preliminary study

Journal of Veterinary Research
Canine mammary gland cancer (CMGC) is the most common neoplastic condition in bitches and is often fatal. There are limited treatment options for CMGC. Primary cell cultures from mammary tumours are promising preclinical in vitro models in which to study
Petrouškova Patŕicia, Hudáková Nikola, Almášiová Viera, Valenčáková Alexandra, Horňáková L’ubica, Huniadi Mykhailo, Čížková Daša   +6 more
doaj   +1 more source

Nucleotide and amino acid sequence of MUC1-TM and MUC1-ARF.

, 2016
MUC1-TM initiation codon is shown in black font and green highlight. Downstream to this initiation codon, three potential MUC1-ARF initiation codons in a +1 frame are shown in red font and green highlight.
John Hilkens (412442), Michael Chalick (3234639), Franz-Georg Hanisch (318572), Armand Bensussan (214677), Oded Jacobi (3234645), Nechama I. Smorodinsky (140867), Tania Zehavi (367263), Ravit Ziv (3234648), Christian Garbar (3234657), Alan Meeker (3234642), Daniel H. Wreschner (3234654), Edward Pichinuk (3234651), Daniel B. Rubinstein (3234636)   +12 more
core   +1 more source

MUC1.Tg mice appeared to elicit MUC1-specific peripheral tolerance.

, 2013
T cells from mice vaccinated with MUC1 DNA or T cells from mice immunized with control vectors (3×106 cells) were mixed with B16-F10-MUC1 cells (5×104 cells) and subcutaneously injected into naïve B6 or MUC1.Tg mice. Survival rates of the mice are shown.
Shigenori Nagai (307307), Ryuichi Murakami (307306), Kazuyoshi Takeda (3940), Daisuke Sugiura (307303), Mitsuyo Takashima (307305), Kaori Denda-Nagai (307304), Tatsuro Irimura (307308)   +6 more
core   +1 more source

Reverse-engineering the anti-MUC1 antibody 139H2 by mass spectrometry–based de novo sequencing

Life Science Alliance
A widely used anti-MUC1 antibody (139H2) is sequenced by mass spectrometry, revealing the molecular basis of its glycosylation-independent binding to this tumor-associated antigen.
Weiwei Peng, Koen CAP Giesbers, Marta Šiborová, J Wouter Beugelink, Matti F Pronker, Douwe Schulte, John Hilkens, Bert JC Janssen, Karin Strijbis, Joost Snijder   +9 more
doaj   +1 more source

Abstract 3330: MUC1* targeting CAR T

, 2017
Purpose: Over 75% of all solid tumor cancers are characterized by aberrant expression of MUC1. Yet to date, no effective MUC1 targeting therapeutic has succeeded.
Luke T. Deary, Andrew K. Stewart, Jared L. Dietz, Cynthia Carol Bamdad, Benoit J. Smagghe, Victoria L. Kohler   +5 more
core   +1 more source

An Ocular Surface-Targeting Nucleic Acid Hydrogel for Efficient Dry Eye Disease Treatment. [PDF]

Exploration (Beijing)
Liu Y, Zhai Z, Huang Y, Wang F, Wang Z, Zhu L, Jiang K, Zhou X, Zhou X, Jie Y, Jin X, Zhang C, Hong J.   +12 more
europepmc   +1 more source